Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. (NTRA) reports that Matthew Rabinowitz, through Morgan Stanley Smith Barney LLC Executive Financial Services, has filed to potentially sell 2,000 shares of Common Stock, valued at $641,800.00. The shares relate to a 03/20/2020 Gift from Affiliate and an acquisition date of 11/26/2003.
The filing also lists recent sales of Natera common stock over the past three months by Rabinowitz and an associated trust, including multiple large transactions in June and smaller sales in July and August 2026.
Natera Inc. shareholder Jonathan Sheena filed to sell common stock under a planned transaction. The notice covers 18,000 shares of common stock to be sold through Charles Schwab & Co., Inc. on NASDAQ, with an indicated aggregate value of $5,951,100.00. The shares relate to ISO stock options originally dated March 9, 2022.
The filing also lists prior open-market sales of Natera common stock during the past three months, including several transactions between May and August 2026, with trade sizes ranging from 109 to 3,150 shares and corresponding dollar amounts disclosed for each sale.
Natera, Inc. reported strong top-line growth in Q2 2026, with total revenues of 752,750 versus 546,600 a year earlier (three-month periods, in thousands of dollars). For the first half of 2026, revenue rose to 1,449,394 from 1,048,431, while net loss narrowed to 66,969 for the quarter and 152,060 year-to-date.
Natera held 1,091,502 in cash, cash equivalents and restricted cash at June 30, 2026, generated 94,964 of operating cash flow in the first half, and had 80,291 of short‑term debt under an 80.3 million Credit Line (all in thousands). Total assets were 2,657,497 and stockholders’ equity 1,821,499, and management believes existing cash will fund operations for at least 12 months.
The results reflect integration of the 424.5 million acquisition of Foresight Diagnostics, which added 141.1 million of goodwill and significant developed technology intangibles, along with 120,505 (thousands) of contingent consideration. Legal matters remain a notable risk, including approximately 33.2 million accrued for legal contingencies and a jury award of 57.0 million in a Ravgen patent case that Natera is appealing.
Natera, Inc. reported strong second-quarter 2026 results, with total revenues of $752.8 million, up 37.7% from $546.6 million a year earlier, and gross margin of 64.5%. The company processed about 1,043,900 tests, including 296,700 oncology tests, and narrowed its net loss to $67.0 million, or $0.47 per share, from $100.9 million, or $0.74 per share, in the prior-year quarter. Cash, cash equivalents and restricted cash were $1,091.5 million at June 30, 2026, with $80.3 million outstanding under a UBS line of credit.
For 2026, Natera anticipates total revenue of $2.85 billion to $2.91 billion, gross margin of 64% to 66%, selling, general and administrative costs of $1.125 billion to $1.225 billion, research and development costs of $800 million to $900 million, and positive cash flow. Operational highlights included record growth in clinical molecular residual disease oncology volumes, three major regulatory approvals for the Signatera assay, expanded Medicare coverage for Prospera, and an enhanced Panorama NIPT with validated performance in low fetal fraction samples.
Natera, Inc. executive Michael Burkes Brophy, the Chief Financial Officer, reported two sales of common stock totaling 795 shares. On August 3, 2026, he sold 317 shares at $267.9893 per share to satisfy tax withholding and remittance obligations arising from the vesting of RSUs, under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. On August 4, 2026, he sold 478 shares at $274.22 per share, with those sales effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025 and modified on September 10, 2025. The filing also checks the Rule 10b5-1 affirmative-defense box, indicating these transactions were executed under Rule 10b5-1 trading arrangements.
Natera, Inc. director, CEO and President Steven Leonard Chapman reported selling 3,076 shares of Common Stock on August 3, 2026. One sale of 1,182 shares at $267.9893 was to satisfy tax withholding and remittance obligations on vesting RSUs under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. Additional tranches, ranging from 70 to 612 shares, were sold under a pre-arranged Rule 10b5-1 trading plan adopted December 11, 2023 and later amended, at per-share or weighted-average prices in ranges such as $263.29–$264.24, $266.58–$267.54 and $267.8350–$268.7700.
Natera, Inc. executive John Fesko, President and Chief Business Officer, reported a sale of 295 shares of common stock on August 3, 2026 at an average price of $267.9893 per share. The sale was effected to satisfy tax withholding and remittance obligations arising from vesting RSUs, pursuant to a written instruction under a Rule 10b5-1(c) Stock Unit Agreement granted on January 31, 2025. Following this transaction, Fesko directly holds 183,774 shares of Natera common stock.
Natera, Inc. executive Solomon Moshkevich, president of clinical diagnostics, reported selling a total of 3,410 shares of common stock on 2026-08-03 in multiple open-market transactions. Per-share prices included $267.9893 and $259.9800. 410 shares were sold to satisfy tax withholding on RSU vesting under instructions intended to meet Rule 10b5-1(c) conditions, and the remaining sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
Natera, Inc. reporting person Daniel Rabinowitz, SEC. and Chief Legal Officer, reported the sale of 334 shares of Common Stock on August 3, 2026 at a per share price of $267.9893. The sale satisfied tax withholding on vesting RSUs under written Rule 10b5-1(c) instructions, leaving 170,073 shares directly held.
Natera, Inc. reports that Executive Chairman Matthew Rabinowitz sold 731 shares of common stock on 2026-08-03 at $267.9893 per share. The sale was effected to cover tax withholding and remittance obligations from RSU vesting under a Rule 10b5-1(c) instruction. After the transaction he holds 2,275,394 shares directly and 4,000 shares indirectly through his spouse.